<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962763</url>
  </required_header>
  <id_info>
    <org_study_id>LM2021230</org_study_id>
    <nct_id>NCT04962763</nct_id>
  </id_info>
  <brief_title>Correlation of Intestinal Flora and Metabolomics in Patients With Ischemic Heart Failure</brief_title>
  <official_title>Correlation of Intestinal Flora and Metabolomics in Patients With Ischemic Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide new ideas for the treatment of patients with ischemic heart failure, this study is&#xD;
      to search for differential metabolic markers associated with ischemic heart failure and to&#xD;
      study the influence of fecal flora on the course of heart failure in patients with ischemic&#xD;
      heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is the final stage of all cardiovascular diseases. Myocardial damage&#xD;
      caused by myocardial infarction, cardiomyopathy, hemodynamic overload, inflammation, or any&#xD;
      other cause, can result in changes in myocardial structure and function, resulting in&#xD;
      ventricular pumping and/or diastolic dysfunction. Among them, ischemic heart disease caused&#xD;
      by coronary artery lesions is the primary cause of heart failure, clinically known as&#xD;
      ischemic heart failure (IHF).&#xD;
&#xD;
      More and more studies have confirmed that the structure and function of the gut and the&#xD;
      substances in the gut play an important role in the pathogenesis of heart failure, and&#xD;
      proposed the &quot;gut hypothesis of heart failure&quot;. Previous studies have shown that regulation&#xD;
      of intestinal flora and its metabolites may improve the progression of patients with heart&#xD;
      failure to some extent, but further studies are still needed to explore whether regulation of&#xD;
      intestinal flora can effectively delay the development of heart failure and thus improve the&#xD;
      prognosis.&#xD;
&#xD;
      This study recruited 150 patients with ischemic heart failure and 50 healthy volunteers&#xD;
      matched with age and sex in the heart failure group required by the researchers plan to&#xD;
      conventional drug treatment of heart failure, but in front of the collection of serum, stool&#xD;
      samples, the patients and healthy volunteers shall be the standard diet, work and rest, time&#xD;
      sampling (that is, the timing acquisition participants in the early morning of 2 g feces and&#xD;
      2 mL fasting venous blood).Metabolic profiles of serum and stool samples from patients with&#xD;
      ischemic heart failure and healthy volunteers were studied using LC-MS, 1H NMR and 16sRNA&#xD;
      based metabolomics and intestinal microbiome methods to identify differential metabolic&#xD;
      markers associated with ischemic heart failure. The feces of patients with ischemic heart&#xD;
      failure were transplanted into model rats to investigate the regulatory effects of the feces&#xD;
      of patients with ischemic heart failure and the feces of healthy volunteers on the structure&#xD;
      of intestinal microflora and related metabolism of normal and model animals, so as to&#xD;
      systematically study the influence of the fecal microflora of patients with ischemic heart&#xD;
      failure on the course of heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Find a new diagnostic method for ischemic heart failure</measure>
    <time_frame>From the end of enrollment to six months</time_frame>
    <description>Identify biomarkers and differential intestinal flora associated with ischemic heart failure</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>To Search for Biomarkers Associated With Ischemic Heart Failure</condition>
  <condition>To Explore the Relationship Between Intestinal Flora and Ischemic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and feces&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        No intervention. All patients diagnosed with ischemic heart failure in the Third Hospital&#xD;
        of Peking University received the current clinical standard treatment plan, and received&#xD;
        clinical follow-up and questionnaire survey according to this plan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Heart Failure Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18;&#xD;
&#xD;
          2. A clear diagnosis of coronary heart disease;&#xD;
&#xD;
          3. NYHA cardiac function grade ≥III and/or LVEF≤40%;&#xD;
&#xD;
          4. Voluntarily signed the informed consent.&#xD;
&#xD;
        Control Inclusion Criteria:&#xD;
&#xD;
          1. The spouse of the case group;&#xD;
&#xD;
          2. Age ≥18;&#xD;
&#xD;
          3. No previous clear diagnosis of coronary heart disease;&#xD;
&#xD;
          4. The LVEF: 50 ~ 80%;&#xD;
&#xD;
          5. Voluntarily signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received major gastrointestinal surgery (including gallbladder and appendectomy)&#xD;
             within 5 years;&#xD;
&#xD;
          2. Inflammatory bowel disease (IBD), including ulcerative colitis, Crohn's disease, or&#xD;
             colitis;&#xD;
&#xD;
          3. Acute gastroenteritis;&#xD;
&#xD;
          4. Clostridium difficile (recurrent) or Helicobacter pylori infection;&#xD;
&#xD;
          5. Persistent or chronic diarrhea;&#xD;
&#xD;
          6. Chronic constipation;&#xD;
&#xD;
          7. Peptic ulcer;&#xD;
&#xD;
          8. Polyps in the stomach or intestines;&#xD;
&#xD;
          9. Gastrointestinal neoplasms;&#xD;
&#xD;
         10. Irritable bowel syndrome;&#xD;
&#xD;
         11. Acute or chronic cholecystitis, hepatitis;&#xD;
&#xD;
         12. Take or inject antibiotics and probiotics in the past 3 months&#xD;
&#xD;
         13. End-stage disease (life expectancy less than 3 months);&#xD;
&#xD;
         14. Pregnant or pregnant during follow-up;&#xD;
&#xD;
         15. Failure to give informed consent (e.g. severe cognitive impairment);&#xD;
&#xD;
         16. The patient has been enrolled in other ongoing clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, Doctor</last_name>
    <phone>13811089790</phone>
    <email>dr_lilei@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, Doctor</last_name>
      <phone>13811089790</phone>
      <email>dr_lilei@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic heart failure</keyword>
  <keyword>biomarkers</keyword>
  <keyword>intestinal flora</keyword>
  <keyword>metabonomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

